Lifesci Capital Has Pessimistic View of CNTA FY2025 Earnings

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Lifesci Capital dropped their FY2025 earnings estimates for Centessa Pharmaceuticals in a report released on Wednesday, November 5th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($1.39) per share for the year, down from their previous estimate of ($1.33). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals’ Q4 2025 earnings at ($0.40) EPS, Q1 2026 earnings at ($0.42) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.45) EPS and FY2026 earnings at ($1.74) EPS.

Other research analysts have also issued reports about the stock. Chardan Capital restated a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Guggenheim restated a “buy” rating and set a $28.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, October 6th. Truist Financial set a $30.00 price objective on Centessa Pharmaceuticals in a report on Wednesday. Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research report on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Wall Street Zen upgraded shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.67.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $22.83 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.12 and a current ratio of 10.11. The firm has a market cap of $3.06 billion, a P/E ratio of -12.48 and a beta of 1.56. The business’s 50 day moving average price is $22.19 and its 200-day moving average price is $17.03. Centessa Pharmaceuticals has a fifty-two week low of $9.60 and a fifty-two week high of $25.42.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02).

Insider Activity at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total value of $134,460.00. Following the completion of the transaction, the general counsel directly owned 105,386 shares in the company, valued at $2,361,700.26. The trade was a 5.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Tia L. Bush sold 35,000 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total value of $840,000.00. Following the sale, the chief technology officer owned 121,503 shares in the company, valued at approximately $2,916,072. This represents a 22.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 145,964 shares of company stock valued at $3,169,861 over the last 90 days. Corporate insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in CNTA. Cutter Capital Management LP grew its position in Centessa Pharmaceuticals by 184.3% in the 1st quarter. Cutter Capital Management LP now owns 418,127 shares of the company’s stock worth $6,013,000 after purchasing an additional 271,051 shares during the period. Cerity Partners LLC purchased a new stake in Centessa Pharmaceuticals during the first quarter valued at $471,000. American Century Companies Inc. lifted its holdings in Centessa Pharmaceuticals by 1.2% in the first quarter. American Century Companies Inc. now owns 1,092,754 shares of the company’s stock valued at $15,714,000 after acquiring an additional 13,046 shares during the period. Wellington Management Group LLP boosted its position in Centessa Pharmaceuticals by 20.6% in the first quarter. Wellington Management Group LLP now owns 138,767 shares of the company’s stock worth $1,995,000 after purchasing an additional 23,660 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in shares of Centessa Pharmaceuticals during the 1st quarter valued at about $3,273,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.